N/A
Manufactured by Advagen Pharma Ltd
22,107 FDA adverse event reports analyzed
Last updated: 2026-04-14
BUSPIRONE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Advagen Pharma Ltd. The most commonly reported adverse reactions for BUSPIRONE HYDROCHLORIDE include FATIGUE, NAUSEA, HEADACHE, ANXIETY, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BUSPIRONE HYDROCHLORIDE.
Out of 10,214 classified reports for BUSPIRONE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 22,107 FDA FAERS reports that mention BUSPIRONE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FATIGUE, NAUSEA, HEADACHE, ANXIETY, DRUG INEFFECTIVE, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Advagen Pharma Ltd in connection with BUSPIRONE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.